Dr Marisa Zuluaga, MD | |
1411 East 31st Street Qic 22123, Highland Hospital, Oakland, CA 94602 | |
(510) 437-4564 | |
(510) 437-4564 |
Full Name | Dr Marisa Zuluaga |
---|---|
Gender | Female |
Speciality | Emergency Medicine |
Experience | 7 Years |
Location | 1411 East 31st Street Qic 22123, Oakland, California |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033415351 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | A162157 (California) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Highland Hospital | Oakland, CA | Hospital |
Alameda Hospital | Alameda, CA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Alameda Health System | 3779494521 | 504 |
News Archive
Preliminary results suggest that patients with aggressive non-Hodgkin's lymphoma in the developing world might benefit from a modified chemotherapy regimen, researchers say.
After a traumatic brain injury, the most harmful damage is caused by secondary swelling of the brain compressed inside the skull. There is no treatment for this.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
Declines in cigarette smoking among Americans since the mid-1950s - particularly since tobacco-control policies and interventions were implemented after the U.S. Surgeon General's Report on Smoking and Health was released in 1964 - prevented nearly 800,000 lung cancer deaths between 1975 and 2000, according to a study led by researchers at Fred Hutchinson Cancer Research Center.
› Verified 7 days ago
Entity Name | Alameda Health System |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1740332931 PECOS PAC ID: 3779494521 Enrollment ID: O20031110000764 |
News Archive
Preliminary results suggest that patients with aggressive non-Hodgkin's lymphoma in the developing world might benefit from a modified chemotherapy regimen, researchers say.
After a traumatic brain injury, the most harmful damage is caused by secondary swelling of the brain compressed inside the skull. There is no treatment for this.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
Declines in cigarette smoking among Americans since the mid-1950s - particularly since tobacco-control policies and interventions were implemented after the U.S. Surgeon General's Report on Smoking and Health was released in 1964 - prevented nearly 800,000 lung cancer deaths between 1975 and 2000, according to a study led by researchers at Fred Hutchinson Cancer Research Center.
› Verified 7 days ago
Entity Name | County Of Santa Clara |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1699885079 PECOS PAC ID: 1254244973 Enrollment ID: O20040113000784 |
News Archive
Preliminary results suggest that patients with aggressive non-Hodgkin's lymphoma in the developing world might benefit from a modified chemotherapy regimen, researchers say.
After a traumatic brain injury, the most harmful damage is caused by secondary swelling of the brain compressed inside the skull. There is no treatment for this.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
Declines in cigarette smoking among Americans since the mid-1950s - particularly since tobacco-control policies and interventions were implemented after the U.S. Surgeon General's Report on Smoking and Health was released in 1964 - prevented nearly 800,000 lung cancer deaths between 1975 and 2000, according to a study led by researchers at Fred Hutchinson Cancer Research Center.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Marisa Zuluaga, MD 2070 Clinton Ave, Alameda, CA 94501-4399 Ph: (510) 522-3700 | Dr Marisa Zuluaga, MD 1411 East 31st Street Qic 22123, Highland Hospital, Oakland, CA 94602 Ph: (510) 437-4564 |
News Archive
Preliminary results suggest that patients with aggressive non-Hodgkin's lymphoma in the developing world might benefit from a modified chemotherapy regimen, researchers say.
After a traumatic brain injury, the most harmful damage is caused by secondary swelling of the brain compressed inside the skull. There is no treatment for this.
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
Declines in cigarette smoking among Americans since the mid-1950s - particularly since tobacco-control policies and interventions were implemented after the U.S. Surgeon General's Report on Smoking and Health was released in 1964 - prevented nearly 800,000 lung cancer deaths between 1975 and 2000, according to a study led by researchers at Fred Hutchinson Cancer Research Center.
› Verified 7 days ago
Daniel Mantuani, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1506 4th Ave Apt 5, Apt 5, Oakland, CA 94606 Phone: 504-390-5474 | |
Jennifer I. Harris, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 275 W Macarthur, Oakland, CA 94611 Phone: 510-752-1000 | |
Benjamin J. Bonnes, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 275 W Macarthur Blvd, Oakland, CA 94611 Phone: 510-752-1000 | |
Richard J. Knight, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 275 W Macarthur Blvd, Oakland, CA 94611 Phone: 510-752-1000 | |
Michael S. Gelfond, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 275 W Macarthur, Oakland, CA 94611 Phone: 510-752-1000 | |
Dr. Kayla Enriquez, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1411 E 31st St, Oakland, CA 94602 Phone: 510-437-4564 | |
Dr. Emily Meilan Sze, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 350 Hawthorne Ave, Oakland, CA 94609 Phone: 510-869-2500 |